Transmembrane phosphatase with tensin homology-derived peptide antigens presented on MHC molecules (TPTE-MHC)

Transmembrane phosphatase with tensin homology (TPTE) is a member of the PTEN phosphoinositide phosphatase family, primarily categorized as a cancer-testis antigen (CTA) due to its restricted expression in normal testicular germ cells and high prevalence in various cancers such as melanoma and prostate cancer (PubMed: 10531331). TPTE-derived peptide antigens are generated through the proteasomal degradation of the TPTE protein and are subsequently presented on the cell surface by Major Histocompatibility Complex (MHC) class I and II molecules (PubMed: 32728218). These complexes are critical for the recognition of malignant cells by the adaptive immune system, specifically by T-cell receptors (TCRs) on cytotoxic and helper T cells. In clinical oncology, these antigens are targeted by immunotherapies like the mRNA vaccine BNT111, which encodes a portion of the TPTE sequence to prime the immune system against tumor cells (PubMed: 32728218). The high tumor specificity of TPTE makes its MHC-presented peptides ideal candidates for precision immunotherapy, minimizing the risk of damage to healthy somatic tissues.

Other names

TPTE-derived peptidesTPTE-MHC complexTransmembrane phosphatase with tensin homology antigensCancer-testis antigen TPTETPTE-derived epitopes

Induction of antigen-specific T-cell responses through the presentation of TPTE-derived peptides on Major Histocompatibility Complex (MHC) molecules to T-cell receptors (TCRs).